The assessment of future RSV immunizations: How to protect all infants?

Bont, Louis; Olivier, C; Herting, Egbert; Esposito, Susanna; Alonso, José Antonio Navarro; Lega, Federico; Mader, Silke; Morioka, Ichiro; Shen, Kunling; Syrogiannopoulos, George A.; Faust, Saul N.; Bozzola, Elena

doi:10.3389/fped.2022.981741

Cited by 11 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our analysis of clinical outcomes revealed a significant larger percentage of children who needed PICU admission in 2020–2021 (9.4% vs 3.2%, p=0,040). Other studies have found an increase in the absolute case numbers per institution above pre-pandemic levels, perhaps related to the extended regional transmission of RSV in a larger RSV-naïve age cohort 25 26 27 . Taking together, the number of RSV-related hospitalizations from 2021–2022 were much higher than the corresponding numbers of SARS-CoV-2 hospitalizations (data not shown).…”

Section: Discussionmentioning

confidence: 87%

Inpatient Rsv-Management 2016–2022: Epidemiology and Adherence to A Bronchiolitis Treatment Standard at a German University Children’s Hospital

Heidtmann,

Baltaci,

Meyer

et al. 2024

Klin Padiatr

View full text Add to dashboard Cite

Background This study analyzes the RSV season 2021/2022 in a referral children’s hospital, compares the epidemiology and illness severity with RSV-infected inpatients from 2016 to 2020 and audits the adherence to our internal therapy standard for RSV bronchiolitis. Material and methods Inpatients with rtPCR-confirmed RSV infection (Jan. 2016 to Jan. 2022). Results The audit comprises 306 RSV inpatients, on average 50 hospitalizations per year; in 03/2020, a rapid RSV Season-Offset was observed. In the winter season 2020/2021, no patient with RSV was hospitalized. Beginning in July, we noticed a rapid increase of RSV-admissions (most cases in Sept./Oct, duration until Dec. 2021; n=53). In 2021–2022, a significant larger share needed PICU admission (9.4% vs 3.2%, p=0.040). Adherence to the internal guidance was low; only 11.8% (n=36) of all patients received supportive treatment without inhalative or systemic medications, 37% of all patients received antibiotics. Conclusions This audit confirms the strong impact of public preventive measures directed against SARS-CoV-2 transmission on RSV epidemiology. Few weeks after easing public COVID-19 restrictions (summer 2021), RSV inpatient cases rapidly increased, lasting until Dec. 2021. The audit of bronchiolitis management revealed surprisingly low adherence to the internal guidance, despite a face-to-face educational session with the attending pediatricians in Oct. 2021. Low adherence resulted in an unnecessary exposure of RSV patients to systemic medications of questionable benefit including antibiotics.

show abstract

Section: Discussionmentioning

confidence: 87%

Inpatient Rsv-Management 2016–2022: Epidemiology and Adherence to A Bronchiolitis Treatment Standard at a German University Children’s Hospital

Heidtmann,

Baltaci,

Meyer

et al. 2024

Klin Padiatr

View full text Add to dashboard Cite

show abstract

“…The need to prepare for RSV mAb licensure and to identify and address gaps in the pathway to policy recommendation and implementation has been highlighted. 45 , 46 To secure access to preventative mAbs for a broad population, revised pathways for this new prophylactic solution are needed, as can already be seen in certain countries like the US and UK. In some countries, such as France, Italy, and Spain, scientific societies have published guidelines on the use of the prophylactic long-acting RSV mAb, targeting all infants during their first year of life to be protected.…”

Section: Discussionmentioning

confidence: 99%

Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections

Weil-Olivier

Nolan

Navarro-Alonso³

et al. 2023

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

New technologies for the prevention of infectious diseases are emerging to address unmet medical needs, in particular, the use of long-acting monoclonal antibodies (mAb) to prevent Respiratory Syncytial Virus (RSV) lower respiratory tract disease in infants during their first RSV season. The lack of precedent for mAbs for broad population protection creates challenges in the assessment of upcoming prophylactic long-acting mAbs for RSV, with associated consequences in legislative and registration categorization, as well as in recommendation, funding, and implementation pathways. We suggest that the legislative and regulatory categorization of preventative solutions should be decided by the effect of the product in terms of its impact on the population and health-care systems rather than by the technology used or its mechanism of action. Immunization can be passive and active, both having the same objective of prevention of infectious diseases. Long-acting prophylactic mAbs work as passive immunization, as such, their recommendations for use should fall under the remit of National Immunization Technical Advisory Groups or other relevant recommending bodies for inclusion into National Immunization Programs. Current regulations, policy, and legislative frameworks need to evolve to embrace such innovative preventative technologies and acknowledge them as one of key immunization and public health tools.

show abstract

“…Additional efforts should be made to potentiate prevention. The future availability of monoclonal antibodies, as well as of other preventive measures, may be of help in reducing the burden and the severity of RSV infection among pediatric patients [ 2 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Respiratory Syncytial Virus Pediatric Hospitalization in the COVID-19 Era

Bozzola

Barni

Villani

2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) globally affects the population, mainly young children, potentially causing hospitalization. During the COVID-19 pandemic, non-pharmacological measures interfered with the circulation of most respiratory viruses. Then, with the discontinuation of restrictive measures, a new scenario appeared. With this scoping review, we want to globally explore whether the RSV paediatric hospitalization rate was influenced by COVID-19. This scoping review was performed according to PRISMA guidelines on PubMed using the Mesh terms “Respiratory Syncytial Viruses”[Mesh] AND “COVID-19”[Mesh] OR “SARS-CoV-2”[Mesh]. Among them, we identified studies pertaining to children and adolescents up to 18 years old hospitalized for RSV, including 18 records in the revision. With the onset of the COVID-19 pandemic, a drastic reduction in RSV hospitalization among the pediatric population in 2020–2021 season has been observed in the Northern and Southern hemispheres. After the relaxing of restrictive measures, unexpected outbreaks happened, leading to increased hospitalization and occupation of pediatric intensive care units.

show abstract

The assessment of future RSV immunizations: How to protect all infants?

Cited by 11 publications

References 44 publications

Inpatient Rsv-Management 2016–2022: Epidemiology and Adherence to A Bronchiolitis Treatment Standard at a German University Children’s Hospital

Inpatient Rsv-Management 2016–2022: Epidemiology and Adherence to A Bronchiolitis Treatment Standard at a German University Children’s Hospital

Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections

Respiratory Syncytial Virus Pediatric Hospitalization in the COVID-19 Era

Contact Info

Product

Resources

About